Navigation Links
DUSA Pharmaceuticals Named to Deloitte's 2010 Technology Fast 500 List of Fastest Growing Companies in North America
Date:10/26/2010

WILMINGTON, Mass., Oct. 26 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology announced today that it has been named to Deloitte's 2010 Technology Fast 500 list.  For the third consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America.  Rankings are based on percentage of fiscal year revenue growth during the period 2005-2009.  DUSA grew annual revenues by 163% during this period.

"DUSA is honored to receive this recognition from Deloitte for the third year in a row," said Bob Doman, DUSA's President and Chief Executive Officer.  "This is a testament to all of the dedicated DUSA employees who, over the years, have contributed to making our Levulan® Photodynamic Therapy (PDT) one of the fastest growing procedures in dermatology."

Levulan PDT is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.  AKs are the most frequently diagnosed skin disease by U.S. dermatologists with over 5 million treatment visits per year.  Through the first six months of 2010, U.S. Levulan revenue grew 34% over the prior year six months.

Technology Fast 500 Selection and Qualifying Criteria

Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.  This ranking is compiled from nominations submitted directly to the Technology Fast 500 website, and public company database research.  Technology Fast 500 award winners for 2010 are selected based on percentage fiscal year revenue growth during the five year period from 2005 to 2009.

To be considered, Technology Fast 500 entrants must meet the following criteria:

  • Must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues.
  • Base-year operating revenues must be at least $50,000 USD or CD, and current-year operating revenues must be at least $5 million USD or CD.
  • Be in business a minimum of five years.
  • Be headquartered in North America.

About Actinic Keratoses

Actinic keratoses are rough-textured, dry, scaly patches on the skin caused by excessive exposure to ultraviolet light, such as sunlight.  They occur most frequently on sun exposed areas such as the face, scalp, ears, neck, hands and arms.  They form on the outermost layer of skin and they can range in color from skin toned to reddish brown.  They can also range in size from as small as a pinhead to larger than a quarter.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products.  Levulan® Kerastick® for topical solution plus DUSA's BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.  DUSA also markets other dermatology products, including the BLU-U without Levulan and ClindaReach®.  DUSA is based in Wilmington, Mass.  Please visit our website at www.dusapharma.com.


'/>"/>
SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast
2. Strativa Pharmaceuticals Signs Agreement With Swedish Orphan Biovitrum Regarding Nascobal®
3. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
4. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
5. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
6. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
7. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
8. Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
9. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
10. Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President
11. MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast ... VNDA ) today announced it will release results for the fourth ... closes. ... will host a conference call at 4:30 PM ET on Wednesday, ... and full year 2016 financial results and other corporate activities. To ...
(Date:1/19/2017)... LONDON , January 19, 2017 Incretin ... Sympathomimetics and Others The global anti-obesity drugs ... the first half of the forecast period and CAGR of 38.7% ... expected to grow at a CAGR of 32.8% from 2016 to ... million in 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... BOCA RATON, Fla. , Jan. 19, 2017 ... ), a medical device company specializing in the ... conditions, such as keloids, with superficial radiation therapy, ... quarter and full year 2016 financial results on Thursday, ... The Company will hold a conference call ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... 21, 2017 , ... Salveo for life, a company that distributes an effervescent ... United States as part of its presence to expand its market reach. , Using ... the productions of nasty toxins as a result of drinking alcohol, eliminating those toxins ...
(Date:1/21/2017)... ... 21, 2017 , ... Northern California Medical Associates (NCMA) is ... multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient surgery, clinical ... this excellent dermatology practice to our group’s medical services,” explains NCMA CEO, Ruth ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... ... , ... Lice Troopers, the lice removal company based in South Florida, has ... holiday season. , “It happens every year around this time,” says owner, Arie ... which is the head-to-head gateway that lice need to spread.” , As children return ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
Breaking Medicine News(10 mins):